Multiprofessional Critical Care Review: Adult 2024 (MCCRCA24ON)-Community-Acquired and Hospital-Acquired Pneumonia, Including VAP

Community-Acquired and Hospital-Acquired Pneumonia, Including VAP

Video Transcription

Video Summary

The presentation provides a comprehensive review of severe pneumonia in the ICU, covering Severe Community-Acquired Pneumonia (CAP), Hospital-Acquired Pneumonia (HAP), and Ventilator-Associated Pneumonia (VAP). Key points include the elimination of healthcare-associated pneumonia from board exams since 2017, the importance of guideline-based treatment for favorable outcomes, and the emphasis on early diagnosis, effective triage, and timely antibiotic therapy. Severe CAP, comprising about 5% of all CAP cases, is associated with high mortality, respiratory failure, and substantial healthcare costs. Risk factors include use of inhaled steroids, immunosuppressed status, age, and mental status alterations. Guidelines mainly focus on empiric treatment but consider local antibiograms and potential resistance. The addition of macrolides and possibly steroids in severe CAP may improve outcomes, although the use of steroids remains dependent on varying guidelines. For VAP prevention, removing the endotracheal tube timely is a critical practice.

Keywords

Severe Pneumonia

ICU

CAP

HAP

VAP

Antibiotic Therapy

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.